Intraoperative 5-HT3 receptor antagonists decrease the prevalence of postoperative delirium in older adults undergoing hip fracture surgery: a single-center retrospective study

Purpose Postoperative delirium (POD) occurs commonly in older adults, resulting in unfavorable outcomes. Several recent clinical studies have suggested that 5-hydroxytryptamine 3 (5-HT 3 ) receptor antagonists can treat and prevent POD. In this retrospective study, the association between 5-HT 3 rec...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of anesthesia 2023-06, Vol.37 (3), p.379-386
Hauptverfasser: Shin, Hyun-Jung, Park, Ji In, Lee, Sohyun, Hwang, Jung-Won, Na, Hyo-Seok
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose Postoperative delirium (POD) occurs commonly in older adults, resulting in unfavorable outcomes. Several recent clinical studies have suggested that 5-hydroxytryptamine 3 (5-HT 3 ) receptor antagonists can treat and prevent POD. In this retrospective study, the association between 5-HT 3 receptor antagonists and POD was investigated in older adults who underwent hip fracture surgery. Methods The electronic medical records of older adults aged ≥ 65 years who underwent hip fracture surgery between January 2011 and June 2018 were reviewed retrospectively. Multivariable logistic regression analysis was used to investigate the association between 5-HT 3 receptor antagonists and the occurrence of POD. In addition to the incidence of POD, anesthesia-, surgery-, and patient-related factors related to POD were evaluated. Results Of the 1025 patients included, 813 (79.3%) were administered 5-HT 3 receptor antagonists intraoperatively; 471 (45.9%) were administered ramosetron, and 342 (33.4%) were administered palonosetron. POD was identified in 242 patients (23.6%). Ramosetron and palonosetron reduced the POD incidence by 53% (odds ratio [OR] 0.47; 95% confidence interval [CI] 0.32‒0.71; P  
ISSN:0913-8668
1438-8359
DOI:10.1007/s00540-023-03169-5